Pictured: Man holding a Chapter 11 bankruptcy filing/iStock, designer491

图为：持有第11章破产申请的男子/iStock，designer491

Acorda Therapeutics on Monday announced that it has voluntarily filed for bankruptcy and is seeking Chapter 11 protections to facilitate the orderly transfer of its assets and the winding down of its business operations.

Acorda Therapeutics周一宣布，它已自愿申请破产，并正在寻求第11章的保护，以促进其资产的有序转移和业务运营的清盘。

The company has also entered into an asset purchase agreement with German biotech Merz Therapeutics, which has agreed to acquire “substantially all” of Acorda’s assets, including its FDA-approved drugs Inbrija (levodopa inhalation powder), Ampyra (dalfampiridine) and Fampyra (fampiridine), for $185 million..

该公司还与德国生物技术公司Merz Therapeutics签订了资产购买协议，该公司同意以1.85亿美元的价格收购Acorda的“大部分”资产，包括其FDA批准的药物Inbrija（左旋多巴吸入粉），Ampyra（达法米啶）和Fampyra（法米啶）。。

The sale will take place through a competitive auction process, with Merz acting as a “stalking horse” bidder.

此次拍卖将通过竞争性拍卖过程进行，Merz将作为“跟踪马”竞拍人。

Acorda’s shares tanked 59% in after-hours trading in reaction to the news, according to Seeking Alpha.

据Seeking Alpha称，Acorda的股价在盘后交易中暴跌59%。

The decision to file for Chapter 11 bankruptcy was made “following an exhaustive process” and lengthy strategic review of its options for the business moving forward, CEO Ron Cohen said in a statement. Acorda contends that filing for bankruptcy “is in the best interest” of stakeholders.

首席执行官罗恩·科恩（RonCohen）在一份声明中表示，申请第11章破产的决定是“经过详尽的过程”并对其未来业务的选择进行了漫长的战略审查后做出的。Acorda辩称，申请破产“符合利益相关者的最佳利益”。

“One of our top priorities is to ensure an uninterrupted supply of our medications to people with multiple sclerosis and Parkinson’s disease,” Cohen added. “We are confident that Merz Therapeutics, if they are the ultimate acquirer, will be able to seamlessly continue serving these patients’ needs.”.

科恩补充道：“我们的首要任务之一是确保多发性硬化症和帕金森病患者不间断地服用我们的药物。”。“我们相信，如果Merz Therapeutics是最终收购者，他们将能够无缝地继续满足这些患者的需求。”。

Acorda’s Chapter 11 proceedings will take place in the U.S. Bankruptcy Court for the Southern District of New York. If the court approves and grants certain protections, Acorda will be able to continue its normal operations as it works to wind down the company’s business.

Acorda的第11章诉讼将在纽约南区美国破产法院进行。如果法院批准并给予某些保护，Acorda将能够继续其正常运营，因为它正在努力结束公司的业务。

Court approval will also allow Acorda to “minimize” the effects of its bankruptcy on employees, clients, patients and other stakeholders, according to the company.

据该公司称，法院的批准还将允许Acorda“最小化”其破产对员工、客户、患者和其他利益相关者的影响。

Monday’s bankruptcy announcement puts an end to Acorda’s years of financial struggles. In 2019, the company launched a restructuring initiative that saw 25% of its employees laid off, in an attempt to save $21 million.

周一的破产公告结束了阿克达多年的财务困境。2019年，该公司启动了一项重组计划，25%的员工被解雇，试图节省2100万美元。

In September 2021, Acorda slashed its headcount by another 15%, hoping to cut costs by around $20 million per year, starting in 2022. The company at the time also shuffled its masthead, including a change in its CCO and COO positions.

2021年9月，Acorda再次削减了15%的员工，希望从2022年开始每年削减约2000万美元的成本。该公司当时还改组了报头，包括更换了首席财务官和首席运营官的职位。

In January 2024, Acorda also lost a high-powered partner when Biogen opted to return the ex-U.S. licensing rights over Fampyra. The termination of the partnership is scheduled to take effect on Jan. 1, 2025.

2024年1月，当Biogen选择归还Fampyra的前美国许可权时，Acorda也失去了一位强大的合作伙伴。合伙企业的终止计划于2025年1月1日生效。

With its bankruptcy announcement on Monday, Acorda joins a growing group of biotech companies that have shuttered their businesses this year.

随着周一宣布破产，Acorda加入了一个不断壮大的生物技术公司集团，这些公司今年已经关闭了业务。

On Monday, Eiger BioPharmaceuticals announced that it also filed for Chapter 11 bankruptcy and would wind down its operations. In January 2024, Athersys revealed that it had gone bankrupt and would divest its assets to its research partner Healios.

周一，Eiger BioPharmaceuticals宣布，它还申请了第11章的破产，并将结束其业务。2024年1月，Athersys透露其已破产，并将资产剥离给其研究合作伙伴Healios。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾大马尼拉。在LinkedIn上联系他，或发电子邮件给他tristan@tristanmanalac.com或tristan.manalac@biospace.com.